The Research and Correspondence Department is seeking an Operational Path B Supervisor to replace an open position. The position primarily oversees Committee Appeals to the Board of Trustees by making sure they are handled correctly, written up properly, and responded to accurately. The position is also responsible for all aspects of supervising a team of 8-10 Analysts who work on both Path A and Path B. This includes meeting individually and as a team on a regular basis; training, developing, evaluating and disciplining staff as needed; and all administrative work associated with supervising staff. This position will participate on and lead special projects/assignments as needed and participate in departmental supervisory responsibilities. The position will always represent the department in a positive and professional manner.
QualificationsThe successful candidate will be positive, encouraging and approachable. S/he will have a proven track record of success supervising teams. S/he will be detailed, efficient and organized in work, experienced in speaking to large and small groups, and will be comfortable navigating technology to work in a hybrid environment. The successful candidate will have exceptional skills in written and verbal communication, time management, leadership and critical thinking. Knowledge of the Health & Welfare Plans and Fund operations strongly encouraged. Understanding of medical terminology is a plus. High school diploma required; college degree preferred.
Company Benefits:
- 10 vacation days
- 12 PTO days
- Flexible hours
- Hybrid work schedule
- 85% tuition reimbursement
- Comprehensive, company paid health insurance
- Company paid pension benefits
- 401(k) plan with company match
- Daily lunch allowance when onsite at our Chicago office
Please be advised that as a condition of employment, Central States is requiring applicants to be fully vaccinated for COVID-19 and up to date in their vaccination, including receiving booster shots, before they start employment with Central States. An individual will be considered “fully vaccinated” two (2) weeks after the second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or two (2) weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen vaccine.